Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial

[1] Davar D(2013)Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach Clin Dermatol 31 237-250

[2] Tarhini AA(2013)Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer Nat Rev Clin Oncol 11 24-37

[3] Kirkwood JM(2018)Cancer immunotherapy beyond immune checkpoint inhibitors J hematol oncol 1 1-25

[4] Drake CG(2016)Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines (in eng) Expert Rev Clin Immunol 12 1347-1357

[5] Lipson EJ(2015)Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors Cancer Biol Med 12 201-208

[6] Brahmer JR(2014)Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity OncoImmunology 1 1167-1168

[7] Marin-Acevedo JA(2014)"Clinical use of dendritic cells for cancer therapy," (in eng) Lancet Oncol 15 e257-e267

[8] Soyano AE(2010)Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 411-422

[9] Dholaria B(2000)Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells J Clin Oncol 18 3894-3903

[10] Knutson KL(2018)"Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors," (in eng) Vaccine 36 3247-3253

[1] Davar D(2013)Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach Clin Dermatol 31 237-250

[2] Tarhini AA(2013)Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer Nat Rev Clin Oncol 11 24-37

[3] Kirkwood JM(2018)Cancer immunotherapy beyond immune checkpoint inhibitors J hematol oncol 1 1-25

[4] Drake CG(2016)Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines (in eng) Expert Rev Clin Immunol 12 1347-1357

[5] Lipson EJ(2015)Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors Cancer Biol Med 12 201-208

[6] Brahmer JR(2014)Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity OncoImmunology 1 1167-1168

[7] Marin-Acevedo JA(2014)"Clinical use of dendritic cells for cancer therapy," (in eng) Lancet Oncol 15 e257-e267

[8] Soyano AE(2010)Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 411-422

[9] Dholaria B(2000)Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells J Clin Oncol 18 3894-3903

[10] Knutson KL(2018)"Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors," (in eng) Vaccine 36 3247-3253